<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NITROSTAT- nitroglycerin tablet </strong><br>Rebel Distributors Corp<br></p></div>
<h1>Nitrostat<span class="Sup">®</span><br>(Nitroglycerin Sublingual Tablets, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c19b143a-2261-4354-8710-be1868f1af98"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">NITROSTAT is a stabilized sublingual compressed nitroglycerin tablet that contains 0.3 mg, 0.4 mg , or 0.6 mg nitroglycerin; as well as lactose monohydrate, NF; glyceryl monostearate, NF; pregelatinized starch, NF; calcium stearate, NF powder; and silicon dioxide, colloidal, NF.</p>
<p>Nitroglycerin, an organic nitrate, is a vasodilating agent. The chemical name for nitroglycerin is 1, 2, 3 propanetriol trinitrate and the chemical structure is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dcb552c1-310a-48af-81ad-a74530531dee&amp;name=dcb552c1-310a-48af-81ad-a74530531dee-01.jpg"></div>
<p>Molecular weight: 227.09</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_a89c3c3c-63fb-4689-82db-ed8eaaf28b4f"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle. Although venous effects predominate, nitroglycerin produces, in a dose-related manner, dilation of both arterial and venous beds. Dilation of postcapillary vessels, including large veins, promotes peripheral pooling of blood, decreases venous return to the heart, and reduces left ventricular end-diastolic pressure (preload). Nitroglycerin also produces arteriolar relaxation, thereby reducing peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and arterial pressure (afterload), and dilates large epicardial coronary arteries; however, the extent to which this latter effect contributes to the relief of exertional angina is unclear.</p>
<p>Therapeutic doses of nitroglycerin may reduce systolic, diastolic, and mean arterial blood pressure. Effective coronary perfusion pressure is usually maintained, but can be compromised if blood pressure <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> excessively, or increased heart rate decreases diastolic filling time.</p>
<p>Elevated central venous and pulmonary capillary wedge pressures, and pulmonary and systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> are also reduced by nitroglycerin therapy. Heart rate is usually slightly increased, presumably due to a compensatory response to the <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>. <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">Cardiac index</span> may be increased, decreased, or unchanged. Myocardial oxygen consumption or demand (as measured by the pressure-rate product, <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>-time index, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>-work index) is decreased and a more favorable supply-demand ratio can be achieved. Patients with elevated left ventricular filling pressures and increased systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> in association with a depressed <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> are likely to experience an improvement in <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span>. In contrast, when filling pressures and <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> are normal, <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> may be slightly reduced following nitroglycerin administration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9dd2368c-ed1a-4441-a824-27f46c5f8aec"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Nitroglycerin forms free radical nitric oxide (NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle, and result in <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f9c0896-737b-45c5-96aa-c80e29c4bb02"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Consistent with the symptomatic relief of angina, digital plethysmography indicates that onset of the vasodilatory effect occurs approximately 1 to 3 minutes after sublingual nitroglycerin administration and reaches a maximum by 5 minutes postdose. Effects persist for at least 25 minutes following NITROSTAT administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5f896b13-07de-41ac-9656-5f9f2a7825f7"></a><a name="section-2.3"></a><p></p>
<h2>Pharmacokinetics and Drug Metabolism Absorption</h2>
<p class="First">Nitroglycerin is rapidly absorbed following sublingual administration of NITROSTAT tablets. Mean peak nitroglycerin plasma concentrations occur at a mean time of approximately 6 to 7 minutes postdose (Table 1). Maximum plasma nitroglycerin concentrations (Cmax) and area under the plasma concentration-time curves (AUC) increase dose-proportionally following 0.3 to 0.6 mg NITROSTAT. The absolute bioavailability of nitroglycerin from NITROSTAT tablets is approximately 40% but tends to be variable due to factors influencing drug absorption, such as sublingual hydration and mucosal metabolism.</p>
<a name="id_5d2c3055-7d3c-419b-8576-995ec5bcd04e"></a><table>
<caption><span>Table 1</span></caption>
<col align="left" width="33%">
<col align="center" width="34%">
<col align="center" width="33%">
<thead>
<tr class="First Toprule">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top">Mean Nitroglycerin (SD) Values</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">2 × 0.3 mg</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">1 × 0.6 mg</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">Parameter</td>
<td class="Rrule" align="left" valign="top">NITROSTAT Tablets</td>
<td class="Rrule" align="left" valign="top">NITROSTAT Tablets</td>
</tr>
</thead>
<tbody>
<tr class="First Toprule">
<td class="Botrule Lrule" align="left" valign="top">Cmax, ng/mL</td>
<td class="Botrule" align="left" valign="top">2.3 (1.7)</td>
<td class="Botrule Rrule" align="left" valign="top">2.1 (1.5)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">Tmax, min</td>
<td class="Botrule" align="left" valign="top">6.4 (2.5)</td>
<td class="Botrule Rrule" align="left" valign="top">7.2 (3.2)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">AUC(0–∞), min</td>
<td class="Botrule" align="left" valign="top">14.9 (8.2)</td>
<td class="Botrule Rrule" align="left" valign="top">14.9 (11.4)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule" align="left" valign="top">t½, min</td>
<td align="left" valign="top">2.8 (1.1)</td>
<td class="Rrule" align="left" valign="top">2.6 (0.6)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c465ff2a-7a0d-43bd-bec9-bc965957f456"></a><a name="section-2.4"></a><p></p>
<h2>Distribution</h2>
<p class="First">The volume of distribution (V<span class="Sub">Area</span>) of nitroglycerin following intravenous administration is 3.3 L/kg. At plasma concentrations between 50 and 500 ng/mL, the binding of nitroglycerin to plasma proteins is approximately 60%, while that of 1,2- and 1,3-dinitroglycerin is 60% and 30%, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ec533e1c-db0a-43f1-ab30-4ef093aaa223"></a><a name="section-2.5"></a><p></p>
<h2>Metabolism</h2>
<p class="First">A liver reductase enzyme is of primary importance in the metabolism of nitroglycerin to glycerol di- and mononitrate metabolites and ultimately to glycerol and organic nitrate. Known sites of extrahepatic metabolism include red blood cells and vascular walls. In addition to nitroglycerin, 2 major metabolites 1,2- and 1,3-dinitroglycerin, are found in plasma. Mean peak 1,2- and 1,3-dinitroglycerin plasma concentrations occur at approximately 15 minutes postdose. The elimination half-life of 1,2- and 1,3-dinitroglycerin is 36 and 32 minutes, respectively. The 1,2- and 1,3-dinitroglycerin metabolites have been reported to possess approximately 2% and 10%, respectively, of the pharmacological activity of nitroglycerin. Higher plasma concentrations of the dinitro metabolites, along with their nearly 10-fold longer elimination half-lives, may contribute significantly to the duration of pharmacologic effect. Glycerol mononitrate metabolites of nitroglycerin are biologically inactive.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fe4f7d82-5906-4b85-9f5f-00cf88d1635c"></a><a name="section-2.6"></a><p></p>
<h2>Elimination</h2>
<p class="First">Nitroglycerin plasma concentrations decrease rapidly, with a mean elimination half-life of 2 to 3 minutes. Half-life values range from 1.5 to 7.5 minutes. Clearance (13.6 L/min) greatly exceeds hepatic blood flow. Metabolism is the primary route of drug elimination.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_69bb6bac-8b95-4524-9522-f6f3dafb20bf"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Nitroglycerin is indicated for the acute relief of an attack or acute prophylaxis of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> due to <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_e58e3d86-72e8-4297-88b0-318c1e1a2cc1"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> to organic nitrates are extremely rare, but they do occur. Nitroglycerin is contraindicated in patients who are allergic to it.</p>
<p>Sublingual nitroglycerin therapy is contraindicated in patients with early <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>, and those with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to nitroglycerin.</p>
<p>Administration of NITROSTAT is contraindicated in patients who are using a phosphodiesterase-5 (PDE-5) inhibitor (e.g., sildenafil citrate, tadalafil, vardenafil hydrochloride) since these compounds have been shown to potentiate the hypotensive effects of organic nitrates.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_8d44bc75-87a2-4d62-90df-58245b222d9e"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">The benefits of sublingual nitroglycerin in patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> have not been established. If one elects to use nitroglycerin in these conditions, careful clinical or hemodynamic monitoring must be used because of the possibility of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_4cca9369-9c6e-43a2-9c8b-536ed13f9c82"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_908457fe-4a22-4bbe-b182-2f31f1dccaa3"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Only the smallest dose required for effective relief of the acute <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">anginal attack</span> should be used. Excessive use may lead to the development of tolerance. NITROSTAT tablets are intended for sublingual or buccal administration and should not be swallowed.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, particularly with upright posture, may occur with small doses of nitroglycerin. This drug should therefore be used with caution in patients who may be volume-depleted or who, for whatever reason, are already hypotensive. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> induced by nitroglycerin may be accompanied by paradoxical <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and increased <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>.</p>
<p>Nitrate therapy may aggravate the angina caused by <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span>.</p>
<p>As tolerance to other forms of nitroglycerin develops, the effects of sublingual nitroglycerin on exercise tolerance, although still observable, is blunted.</p>
<p>In industrial workers who have had long-term exposure to unknown (presumably high) doses of organic nitrates, tolerance rarely occurs. <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, and even <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have occurred during temporary withdrawal of nitrates from these workers, demonstrating the existence of true physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<p>Several clinical trials of nitroglycerin patches or infusions in patients with <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> have evaluated regimens that incorporated a 10- to 12-hour nitrate free interval. In some of these trials, an increase in the frequency of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">anginal attacks</span> during the nitrate free interval was observed in a small number of patients. In one trial, patients had decreased exercise tolerance at the end of the nitrate interval. Hemodynamic rebound has been observed only rarely; on the other hand, few studies were so designed that rebound, if it had occurred, would have been detected.</p>
<p>Nitrate tolerance as a result of sublingual nitroglycerin administration is probably possible, but only in patients who maintain high continuous nitrate levels for more than 10 or 12 hours daily. Such use of sublingual nitroglycerin would entail administration of scores of tablets daily and is not recommended.</p>
<p>The drug should be discontinued if <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span> or drying of the mouth occurs. Excessive dosage of nitroglycerin may produce severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_a2113fac-2194-4b9f-9efd-a2289b300377"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">NITROSTAT is a sublingual tablet and should not be chewed, crushed, or swallowed.</p>
<p>If possible, patients should sit down when taking NITROSTAT tablets and should use caution when returning to a standing position. This eliminates the possibility of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> due to <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>One tablet should be dissolved under the tongue or in the buccal pouch at the first sign of an acute <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">anginal attack</span>. The dose may be repeated approximately every 5 minutes until relief is obtained. </p>
<p>If <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> persists after a total of 3 tablets in a 15-minute period, or if the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is different than is typically experienced, prompt medical attention is recommended.</p>
<p>NITROSTAT may be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.</p>
<p>Nitroglycerin may produce a burning or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling sensation</span> when administered sublingually; however, the ability to produce a burning or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling sensation</span> should not be considered a reliable method for determining the potency of the tablets.</p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span> can sometimes accompany treatment with nitroglycerin. In patients who get these <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> may be a marker of the activity of the drug.</p>
<p>Treatment with nitroglycerin may be associated with <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> upon standing, especially just after rising from a recumbent or seated position. This effect may be more frequent in patients who have also consumed alcohol.</p>
<p>Nitroglycerin should be kept in the original glass container and must be tightly capped after each use to prevent loss of tablet potency.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_14f211a8-0184-402f-a02b-d650c56f84cc"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Patients receiving antihypertensive drugs, beta-adrenergic blockers, or phenothiazines and nitrates should be observed for possible additive hypotensive effects. Marked <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> has been reported when calcium channel blockers and organic nitrates were used concomitantly.</p>
<p>Concomitant use of nitrates and alcohol may cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>The vasodilatory and hemodynamic effects of nitroglycerin may be enhanced by concomitant administration of aspirin.</p>
<p>Intravenous administration of nitroglycerin decreases the thrombolytic effect of alteplase. Therefore, caution should be observed in patients receiving sublingual nitroglycerin during alteplase therapy.</p>
<p>Intravenous nitroglycerin reduces the anticoagulant effect of heparin and <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin times</span> (APTT) should be monitored in patients receiving heparin and intravenous nitroglycerin. It is not known if this effect occurs following single sublingual nitroglycerin doses.</p>
<p>Tricyclic antidepressants (amitriptyline, desipramine, doxepin, others) and anticholinergic drugs may cause <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and diminished salivary secretions. This may make dissolution of sublingual nitroglycerin difficult. Increasing <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> with chewing gum or artificial saliva products may prove useful in aiding dissolution of sublingual nitroglycerin.</p>
<p>Oral administration of nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine and subsequently increases its oral bioavailability. Ergotamine is known to precipitate <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>. Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> if this is not possible.</p>
<p>Administration of nitroglycerin is contraindicated in patients who are using PDE-5 inhibitors (e.g., sildenafil citrate, tadalafil, vardenafil hydrochloride). These compounds have been shown to potentiate the hypotensive effects of organic nitrates.</p>
<p>A decrease in therapeutic effect of sublingual nitroglycerin may result from use of long-acting nitrates.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_45244654-7d5e-4ab4-8aa4-324d43825102"></a><a name="section-6.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Nitrates may interfere with the Zlatkis-Zak color reaction, causing a false report of decreased serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_c1b23f03-7ee9-4e15-90e4-f1c0a2c1d844"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Animal carcinogenesis studies with sublingually administered nitroglycerin have not been performed.</p>
<p>Rats receiving up to 434 mg/kg/day of dietary nitroglycerin for 2 years developed dose-related fibrotic and neoplastic changes in liver, including carcinomas, and interstitial cell tumors in testes. At high dose, the incidences of hepatocellular carcinomas in males was 48% and in females was 33%, compared to 0% in untreated controls. Incidences of testicular tumors were 52% vs. 8% in controls. Lifetime dietary administration of up to 1058 mg/kg/day of nitroglycerin was not tumorigenic in mice.</p>
<p>Nitroglycerin was weakly mutagenic in Ames tests performed in 2 different laboratories. Nevertheless, there was no evidence of mutagenicity in an <span class="Italics">in vivo</span> dominant lethal assay with male rats treated with doses up to about 363 mg/kg/day, PO, or in <span class="Italics">ex vivo</span> cytogenetic tests in rat and dog tissues.</p>
<p>In a 3-generation reproduction study, rats received dietary nitroglycerin at doses up to about 434 mg/kg/day for 6 months prior to mating of the F<span class="Sub">0 </span>generation, with treatment continuing through successive F<span class="Sub">1</span> and F<span class="Sub">2</span> generations. The high dose was associated with decreased feed intake and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in both sexes at all matings. No specific effect on the fertility of the F<span class="Sub">0</span> generation was seen. <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span> noted in subsequent generations, however, was attributed to increased interstitial cell tissue and aspermatogenesis in the high-dose males. In this 3-generation study, there was no clear evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b759820c-c70c-41b0-a3cc-f5044c341293"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">Animal reproduction and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> studies have not been conducted with nitroglycerin sublingual tablets. Teratology studies in rats and rabbits, however, were conducted with topically applied nitroglycerin ointment at doses up to 80 mg/kg/day and 240 mg/kg/day, respectively. No toxic effects on dams or fetuses were seen at any dose tested.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Nitroglycerin should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_8b207f73-8580-4853-8d03-dc5f8847a65f"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether nitroglycerin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nitroglycerin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_b33e9058-c1ec-47f4-8129-e438cef809e9"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of nitroglycerin in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_8bbe18a4-cdc7-420c-940b-c2299d4f9f36"></a><a name="section-6.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of NITROSTAT did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_d4ce2e87-c136-4152-b190-cdc2511de61c"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> that may be severe and persistent may occur immediately after use. <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, and other manifestations of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> may develop occasionally, particularly in erect, immobile patients. Marked sensitivity to the hypotensive effects of nitrates (manifested by <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, and collapse) may occur at therapeutic doses. <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> due to nitrate <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> has been reported. <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span>, and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> have been reported in patients receiving nitrate therapy.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_ad39fdb6-a65a-4c73-9c4f-f05d4cf0e750"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="Bold">Hemodynamic Effects:</span> The effects of nitroglycerin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are generally the results of nitroglycerin's capacity to induce <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>, venous pooling, reduced <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. These hemodynamic changes may have protean manifestations, including <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>, with any or all of persistent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">throbbing headache</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and moderate <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>; <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (possibly with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span> and even <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>); <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (especially in the upright posture); <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, later followed by reduced ventilatory effort; <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, with the skin either <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span>; <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>; <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>; and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>No specific antagonist to the vasodilator effects of nitroglycerin is known, and no intervention has been subject to controlled study as a therapy of nitroglycerin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Because the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with nitroglycerin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is the result of venodilatation and arterial <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, prudent therapy in this situation should be directed toward increase in central fluid volume. Passive elevation of the patient's legs may be sufficient, but intravenous infusion of normal saline or similar fluid may also be necessary.</p>
<p>The use of epinephrine or other arterial vasoconstrictors in this setting is likely to do more harm than good.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, therapy resulting in central volume expansion is not without hazard. Treatment of nitroglycerin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in these patients may be subtle and difficult, and invasive monitoring may be required.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span>:</span> <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> has been rarely reported in association with organic nitrates. The diagnosis should be suspected in patients who exhibit signs of impaired oxygen delivery despite adequate <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and adequate arterial PO<span class="Sub">2</span>. Classically, methemoglobinemic blood is described as chocolate brown, without color change on exposure to air.</p>
<p>If <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> is present, intravenous administration of methylene blue, 1 to 2 mg/kg of body weight, may be required.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_3e66745e-1aa7-4b85-b41d-1a70c806acef"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">One tablet should be dissolved under the tongue or in the buccal pouch at the first sign of an acute <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">anginal attack</span>. The dose may be repeated approximately every 5 minutes until relief is obtained. If the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> persists after a total of 3 tablets in a 15-minute period, or if the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is different than is typically experienced, prompt medical attention is recommended. NITROSTAT may be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.</p>
<p>During administration the patient should rest, preferably in the sitting position.</p>
<p>No dosage adjustment is required in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_ca29fb7d-99a7-4915-b471-6b825fce3c25"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NITROSTAT is supplied as white, round, flat-faced tablets in 3 strengths (0.3 mg, 0.4 mg, and 0.6 mg) in bottles containing 100 tablets each, with color-coded labels, and in color-coded Patient Convenience Packages of 4 bottles of 25 tablets each.</p>
<a name="id_89d1cc50-d2f1-40cc-8f84-943815671160"></a><table>
<col align="left" width="20%">
<col align="left" width="80%">
<tbody class="Headless"><tr class="Botrule First Last">
<td align="left" valign="top">0.4 mg:</td>
<td align="left" valign="top">Coded "N" on one side and "4" on the other.<br>NDC 21695-450-00 — Bottle of 100 tablets</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_5460ca8f-a95d-4078-825d-3d9245c9909e"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Store at Controlled Room Temperature 20°–25°C (68°–77°F) [see USP].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b819b57-72f3-49f5-957b-2943a2ad7033"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dcb552c1-310a-48af-81ad-a74530531dee&amp;name=dcb552c1-310a-48af-81ad-a74530531dee-02.jpg"></p>
<p>LAB-0180-4.0</p>
<p>May 2011</p>
<p>Repackaged by:</p>
<p>Rebel Distributors Corp</p>
<p>Thousand Oaks, CA 91320</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_8da7c7d3-241e-4cc6-912d-f882924abd7e"></a><a name="section-12"></a><p></p>
<h1>Nitrostat<span class="Sup">®</span><br>(Nitroglycerin Sublingual Tablets, USP)</h1>
<p class="First">Read this information carefully before you start <span class="Bold">NITROSTAT<span class="Sup">®</span></span> (NYE-troe-stat) and each time you refill your prescription. There may be new information. This information does not replace talking with your doctor. If you have any questions about <span class="Bold">NITROSTAT</span>, ask your doctor. Your doctor will know if <span class="Bold">NITROSTAT</span> is right for you.</p>
<p><span class="Bold">What is NITROSTAT? </span></p>
<p><span class="Bold">NITROSTAT</span> is a type of medicine known as an organic nitrate and is a vasodilating agent. It is used to treat a type of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> called angina.</p>
<p><span class="Bold">What is Angina? </span></p>
<p>Angina is a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> that keeps coming back when part of your heart does not get enough blood. Angina feels like a pressing or squeezing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, usually in your chest under the breastbone. Sometimes you can feel it in your shoulders, arms, neck, jaws, or back. <span class="Bold">NITROSTAT</span> can relieve this <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. </p>
<p><span class="Bold">Who should not use NITROSTAT?</span></p>
<p>Do not use <span class="Bold">NITROSTAT</span> if you are allergic to organic nitrates (like the active ingredient in <span class="Bold">NITROSTAT</span>).</p>
<p>You should not take <span class="Bold">NITROSTAT</span> if you have the following conditions:</p>
<ul>
<li>very recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li>severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></li>
<li>increased pressure in the head</li>
</ul>
<p>Do not take <span class="Bold">NITROSTAT</span> with drugs for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, like VIAGRA<span class="Sup">®</span> (sildenafil citrate), CIALIS<span class="Sup">®</span> (tadalafil), or LEVITRA<span class="Sup">®</span> (vardenafil hydrochloride), as this may lead to extreme lowering of your blood pressure<span class="Italics">.</span></p>
<p><span class="Bold">What should I tell my doctor before taking NITROSTAT?</span></p>
<p>Before using <span class="Bold">NITROSTAT</span>, tell your doctor if:</p>
<ul>
<li>You are taking any medicines that are used to treat angina, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or an irregular heartbeat.</li>
<li>You are taking any medicines that reduce blood pressure.</li>
<li>You are taking any diuretics (water pills). </li>
<li>You are taking medications to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or psychiatric illness.</li>
<li>You are taking ergotamine or similar drugs for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>.</li>
<li>You are taking aspirin.</li>
<li>You are taking the blood thinner medicine heparin. </li>
<li>You are taking any medicines for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>. </li>
<li>You are pregnant or plan to become pregnant.</li>
<li>You are breastfeeding. </li>
</ul>
<p><span class="Bold">How should I take NITROSTAT?</span></p>
<ul>
<li>Do not chew, crush, or swallow <span class="Bold">NITROSTAT</span> tablets.</li>
<li>You should sit down when taking <span class="Bold">NITROSTAT</span> tablets and use caution when you stand up. This eliminates the possibility of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> due to <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</li>
<li>One tablet should be dissolved under the tongue or in the oral cavity at the first sign of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>.</li>
<li>The dose may be repeated approximately every 5 minutes, until the <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> is relieved.</li>
<li>If the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> persists after a total of 3 tablets in a 15-minute period, or is different than you typically experience, call your doctor or seek emergency help. </li>
<li>
<span class="Bold">NITROSTAT</span> may be used 5 to 10 minutes prior to activities that might cause <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>.</li>
<li>You may feel a burning or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling sensation</span> in your mouth when you take <span class="Bold">NITROSTAT</span>.</li>
</ul>
<p><span class="Bold">What should I avoid while taking NITROSTAT?</span></p>
<ul>
<li>Do not breastfeed. It is not known if <span class="Bold">NITROSTAT</span> will pass through your milk.</li>
<li>Do not consume alcohol while taking <span class="Bold">NITROSTAT</span>, as this can lower your blood pressure.</li>
<li>Do not start any new prescription or non-prescription medicines or supplements, unless you check with your doctor first.</li>
</ul>
<p><span class="Bold">What are the possible side effects of NITROSTAT?</span></p>
<p><span class="Bold">NITROSTAT</span> may cause the following side effects:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> (a major symptom of <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">balance disorder</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li>heart <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> (unusual awareness of the heartbeat)</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> upon rising from a seated position</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li>paleness</li>
<li><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
<li><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> (warm or red condition of your skin)</li>
<li>other <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> that may be severe</li>
</ul>
<p><span class="Bold">NITROSTAT</span> may cause a false test result of decreased serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. </p>
<p>Tell your doctor if you are concerned about any side effects you experience. These are not all the possible side effects of <span class="Bold">NITROSTAT</span>. For a complete list, ask your doctor or pharmacist.</p>
<p><span class="Bold">How do I store NITROSTAT?</span></p>
<p><span class="Bold">NITROSTAT</span> should be kept in the original glass container and tightly capped after each use to prevent loss of tablet potency.</p>
<p>Store <span class="Bold">NITROSTAT</span> tablets at room temperature (between 68° and 77°F). </p>
<p><span class="Bold">General advice about NITROSTAT</span></p>
<p>Sometimes doctors will prescribe a medicine for a condition that is not included in the patient information leaflets. Only use <span class="Bold">NITROSTAT</span> the way your doctor told you to. Do not give <span class="Bold">NITROSTAT</span> to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>You can ask your pharmacist or doctor for information about <span class="Bold">NITROSTAT</span>, or you can visit the Pfizer website at <span class="Bold">www.pfizer.com</span> or call 1-800-438-1985.</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dcb552c1-310a-48af-81ad-a74530531dee&amp;name=dcb552c1-310a-48af-81ad-a74530531dee-03.jpg"></p>
<p>LAB-0422-1.0 <br>May 2011</p>
<p>Repackaged by:</p>
<p>Rebel Distributors Corp</p>
<p>Thousand Oaks, CA 91320</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_2add13d7-5573-49a6-97b3-3433e2b3ff93"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 0.4 mg Tablet Bottle Label</h1>
<div class="Figure">
<img alt="Nitrostat 0.4mg (1/150gr)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dcb552c1-310a-48af-81ad-a74530531dee&amp;name=dcb552c1-310a-48af-81ad-a74530531dee-04.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NITROSTAT 		
					</strong><br><span class="contentTableReg">nitroglycerin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-450(NDC:0071-0418)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>nitroglycerin</strong> (nitroglycerin) </td>
<td class="formItem">nitroglycerin</td>
<td class="formItem">0.4 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>glyceryl monostearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>calcium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">4mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">N;4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-450-00</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021134</td>
<td class="formItem">05/01/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Rebel Distributors Corp
							(118802834)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rebel Distributors Corp</td>
<td class="formItem"></td>
<td class="formItem">118802834</td>
<td class="formItem">RELABEL, REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dcb552c1-310a-48af-81ad-a74530531dee</div>
<div>Set id: dcb552c1-310a-48af-81ad-a74530531dee</div>
<div>Version: 1</div>
<div>Effective Time: 20120216</div>
</div>
</div> <div class="DistributorName">Rebel Distributors Corp</div></p>
</body></html>
